“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
On Disclosure of Payments and other Transfers of Values (TOV) to patient organisations.
Lupin Healthcare (UK) Ltd “Lupin” is committed to working in an open and transparent way with patient Organisations, in order to better serve the needs of patients. We are working in collaboration with the Association of the British Pharmaceutical Industry (ABPI) in order to make sure that we continue to set high standards of ethical interaction between Lupin Healthcare (UK) Ltd and patient organisations within the UK.
2. Reporting Period
This data pertains to payments corresponding directly or indirectly from Lupin Healthcare (UK) Ltd To patient organisations which took place from 1st January 2019 to 31st December 2019.
3. Financial considerations
All transactions have been correctly accounted for, for both VAT and corporation tax purposes. All company transactions (whether subject to the disclosure of transfer of value or not) are reviewed as part of our annual financial and tax audit procedures. All amounts shown are exclusive of VAT.
4. Criteria for Inclusion/Exclusion
The disclosures include no more than is required by the ABPI Code. Information declared includes transfers of values that have been made. Transfers of value are declared according to the year in which the payment (transfer of value) took place. If an activity took place in this reporting period but was paid in 2020, it will be included in the year the transfer of value (payment) took place.
Cross border engagement: No cross border TOV took place
Non-monetary transfers of value: Disclosure of non-monetary transfers of value is made at the equivalent value in monetary terms.
Multi-year contracts: No multi-year contracts took place for the reporting period.
5. Management of recipients’ queries
Lupin has an email address provided which is responsible for any transfer of value queries.
Any questions on the content here should be referred to firstname.lastname@example.org
Vinita Gupta is the CEO of Lupin Limited (Lupin) and Chairperson of Lupin Inc., (LI) and its US subsidiary, Lupin Pharmaceutical Inc. (LPI).
Vinita is a graduate in pharmacy from the University of Mumbai and earned an MBA degree at the Kellogg School of Management at Northwestern University. Vinita has been instrumental in formulating and executing a strategy that has helped the company emerge as a global pharmaceutical powerhouse; amongst the most exciting growth stories in the pharmaceutical industry. Through a combination of organic growth and strategic acquisitions, she has led the company’s global expansion plans. In particular, she founded, led and established Lupin’s largest region, the United States.
Vinita has been regularly named by Forbes Asia in its Top 50 Power Business women listings for Asia Pacific. Vinita was also recognized by Business Today Hall of Fame – Most Powerful Women in Business in 2016 and was recently named Outstanding Business Woman Leader of the Year by CNBC India Business Leader Awards. She was the winner of the inaugural EY, U.S. 2012 Family Business Award of Excellence and EY Entrepreneur Of the Year® 2012 award winner for Health Services and Technology in Maryland. She is regarded as amongst the most influential Indian Business Women globally.
Vinita along with her brother Nilesh (Managing Director, Lupin Limited) were named Ernst & Young (EY) Entrepreneur of The Year 2015 and won the Forbes India Leadership Awards 2016, Entrepreneur of the Year.
In 2017 Vinita was appointed to the board of directors for Intrexon Corporation. She is also a member of the Global Advisory Board at the Kellogg School of Management at Northwestern University.
Mr. Nilesh Gupta is the MD of Lupin Limited and a member of the Board of Directors. Having joined Lupin in 1996, Mr. Gupta led Lupin’s research, supply chain, manufacturing, quality and regulatory operations, and took charge as the company’s Managing Director in 2013. He has not only been responsible for transforming Lupin’s research program and expanding the company’s manufacturing operations but has also been instrumental in formulating and executing the core strategy that has helped Lupin emerge as a global specialty pharmaceutical major.
Mr. Gupta, along with his sister Vinita Gupta, won the Entrepreneur of the Year award at Forbes India Leadership Awards in 2016 as well as Ernst & Young ‘Entrepreneur of the Year Award’ in India in 2015, also with his sister Vinita Gupta.
Mr. Gupta is a Chemical Engineer from the University Department of Chemical Technology (UDCT) (now ICT), Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.